Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
6 studies found for:    weill AND platelet survival | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Conditions: Thrombotic Microangiopathy;   Disorder Related to Bone Marrow Transplantation
Intervention: Drug: eculizumab
2 Recruiting Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With LDAC in Patients With Previously Untreated AML
Condition: Acute Myeloid Leukemia (AML)
Intervention: Drug: BP1001 in combination with LDAC
3 Recruiting Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Conditions: Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic
Interventions: Drug: Guadecitabine;   Other: Treatment Choice
4 Recruiting Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Conditions: Myelodysplastic Syndrome;   MDS;   Refractory Anemia With Excess Blasts;   RAEB
Interventions: Drug: rigosertib;   Drug: Any approved or standard-of-care therapy;   Drug: best supportive care (BSC)
5 Recruiting A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Cobimetinib;   Drug: Idasanutlin;   Drug: Venetoclax
6 Recruiting A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)
Condition: Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Interventions: Drug: Venetoclax;   Drug: Azacitidine

Study has passed its completion date and status has not been verified in more than two years.